Synthetic Biologics Inc. (SYN)

Trade SYN now with
12/14/2021 7:07:37 AM Synthetic Biologics Announces Planned Transformative Acquisition Of VCN Biosciences
10/21/2021 7:11:28 AM Synthetic Biologics Begins Phase 1 Multiple-Ascending Dose Clinical Trial For SYN-020 Intestinal Alkaline Phosphatase
8/3/2021 7:20:46 AM Synthetic Biologics Expands Option For License Agreement With Massachusetts General Hospital
6/29/2021 7:25:25 AM Synthetic Biologics: Completes Patient Dosing, Observation In Phase 1 Trial Of SYN-020 Intestinal Alkaline Phosphatase
5/26/2021 7:02:42 AM Synthetic Biologics Regains Compliance With NYSE American Continued Listing Standards
4/14/2021 7:09:48 AM Synthetic Biologics Doses First Patient In Phase 1b/2a Clinical Trial Of SYN-004 In Allogeneic HCT Recipients
4/1/2021 7:09:21 AM Synthetic Biologics Says Six Study Participants Dosed In Phase 1a Single-ascending Dose Clinical Trial Of SYN-020 IAP
2/26/2016 8:43:47 AM FBR Capital Markets Initiates Synthetic Biologics Inc. (SYN) At Outperform With $10 Price Target
10/13/2015 7:50:50 AM RBC Capital Markets Starts Synthetic Biologics Inc. (SYN) At Outperform With $2.27 Price Target